{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T18:12:41Z","timestamp":1788631961913,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Racial and Ethnic Health Disparities"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>African American men bear an unequal proportion of metastatic prostate cancer burden. The utilization of second-generation anti-androgens like abiraterone with androgen deprivation therapy (ADT) has become a standard therapy for metastatic prostate cancer. Thus, we aimed to examine the utilization of abiraterone with ADT in African American men with metastatic disease and determine whether disparities in its use exist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective study, using a multi-institutional regional collaborative prostate cancer database. We compared the use of ADT with abiraterone between African American men and non-African American men diagnosed with distantly metastatic prostate cancer from July 2015 to August 2022, using logistic regression and negative binomial regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 201 men with metastatic prostate cancer and of those, 28% were African American men. African American men were younger (47% vs. 27.8%,\u2009\u2264\u200969\u00a0years,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), and younger men experienced a longer time between diagnosis of metastatic disease and receipt of ADT with abiraterone compared to older men (mean 125 vs. 14\u00a0days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.038). While African American and non-African American men had similar rates of ADT use with abiraterone, African American men experienced longer times between documented metastatic disease and initiation of ADT with abiraterone (mean 187 vs. 79\u00a0days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The initiation of ADT with abiraterone was delayed by 3\u00a0months in African American men. This discrepancy warrants an investigation of system level barriers to the timely initiation of abiraterone in African American men given its known oncologic benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40615-025-02533-3","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T10:57:40Z","timestamp":1750762660000},"page":"3757-3764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigating the Usage of Abiraterone in African American Men with Metastatic Prostate Cancer"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-7883","authenticated-orcid":false,"given":"Christine","family":"Ibilibor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Tomaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Ginzburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Uzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Smaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Danella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Belkoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay D.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir S.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"issue":"1","key":"2533_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2533_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44027","volume":"5","author":"K Yamoah","year":"2022","unstructured":"Yamoah K, Lee KM, Awasthi S, Alba PR, Perez C, Anglin-Foote TR, et al. Racial and ethnic disparities in prostate cancer outcomes in the veterans affairs health care system. JAMA Netw Open. 2022;5(1): e2144027.","journal-title":"JAMA Netw Open"},{"issue":"27","key":"2533_CR3","doi-asserted-by":"publisher","first-page":"5375","DOI":"10.1021\/jm981017j","volume":"41","author":"M Jarman","year":"1998","unstructured":"Jarman M, Barrie SE, Llera JM. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem. 1998;41(27):5375\u201381.","journal-title":"J Med Chem"},{"issue":"5928","key":"2533_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787\u201390.","journal-title":"Science"},{"issue":"2","key":"2533_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/oncolo\/oyab045","volume":"27","author":"JJ Orme","year":"2022","unstructured":"Orme JJ, Pagliaro LC, Quevedo JF, Park SS, Costello BA. Rational second-generation antiandrogen use in prostate cancer. Oncologist. 2022;27(2):110\u201324.","journal-title":"Oncologist"},{"issue":"32","key":"2533_CR6","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974\u201386.","journal-title":"J Clin Oncol"},{"key":"2533_CR7","doi-asserted-by":"crossref","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13\u201324.","DOI":"10.1056\/NEJMoa1903307"},{"issue":"2","key":"2533_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"2533_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352\u201360.","journal-title":"N Engl J Med"},{"issue":"4","key":"2533_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338\u201351.","journal-title":"N Engl J Med"},{"issue":"6","key":"2533_CR11","doi-asserted-by":"publisher","first-page":"pkab082","DOI":"10.1093\/jncics\/pkab082","volume":"5","author":"CJD Wallis","year":"2021","unstructured":"Wallis CJD, Malone S, Cagiannos I, Morgan SC, Hamilton RJ, Basappa NS, et al. Real-world use of androgen-deprivation therapy: intensification among older canadian men with de novo metastatic prostate cancer. JNCI Cancer Spectr. 2021;5(6):pkab082.","journal-title":"JNCI Cancer Spectr"},{"key":"2533_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.urology.2021.09.004","volume":"163","author":"AR Esdaille","year":"2022","unstructured":"Esdaille AR, Ibilibor C, Holmes A 2nd, Palmer NR, Murphy AB. Access and representation: a narrative review of the disparities in access to clinical trials and precision oncology in Black men with prostate cancer. Urology. 2022;163:90\u20138.","journal-title":"Urology"},{"issue":"10","key":"2533_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10): e296.","journal-title":"PLoS Med"},{"issue":"9","key":"2533_CR14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/j.1464-410X.2007.07405.x","volume":"101","author":"NL Keating","year":"2008","unstructured":"Keating NL, O\u2019Malley AJ, McNaughton-Collins M, Oh WK, Smith MR. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int. 2008;101(9):1077\u201383.","journal-title":"BJU Int"},{"issue":"4","key":"2533_CR15","first-page":"420","volume":"29","author":"KT Lucero","year":"2023","unstructured":"Lucero KT, Obodozie-Ofoegbu OO, Nooruddin Z, Ryan K, Castillo A, Moore AM, et al. Health disparity in use of novel agents for first-line therapy in Black and White patients with chronic lymphocytic leukemia in the Department of Veterans Affairs. J Manag Care Spec Pharm. 2023;29(4):420\u201330.","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"2533_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.45906","volume":"6","author":"TM Ma","year":"2023","unstructured":"Ma TM, Agarwal N, Mahal B, Barragan-Carrillo R, Spratt D, Rettig MB, et al. Racial and ethnic disparities in use of novel hormonal therapy agents in patients with prostate cancer. JAMA Netw Open. 2023;6(12): e2345906.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2533_CR17","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1200\/OP.21.00168","volume":"18","author":"AY Jeong","year":"2022","unstructured":"Jeong AY, Schwartz EB, Roman AR, McDevitt RL, Oerline MK, Henry E, et al. Characterizing out-of-pocket payments and financial assistance for patients prescribed abiraterone and enzalutamide at an academic cancer center specialty pharmacy. JCO Oncol Pract. 2022;18(2):e284\u201392.","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"2533_CR18","first-page":"217","volume":"45","author":"D Gori","year":"2019","unstructured":"Gori D, Dulal R, Blayney DW, Brooks JD, Fantini MP, McDonald KM, et al. Utilization of prostate cancer quality metrics for research and quality improvement: a structured review. Jt Comm J Qual Patient Saf. 2019;45(3):217\u201326.","journal-title":"Jt Comm J Qual Patient Saf"}],"container-title":["Journal of Racial and Ethnic Health Disparities"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-025-02533-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40615-025-02533-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-025-02533-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:39:10Z","timestamp":1788629950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40615-025-02533-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2533"],"URL":"https:\/\/doi.org\/10.1007\/s40615-025-02533-3","relation":{},"ISSN":["2197-3792","2196-8837"],"issn-type":[{"value":"2197-3792","type":"print"},{"value":"2196-8837","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board at each author\u2019s respective institution.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}